Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) plus ponatinib vs. HCVAD plus dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL).

被引：1
|
作者：
Sasaki, Koji
Kantarjian, Hagop M.
Ravandi, Farhad
Thomas, Deborah A.
Daver, Naval Guastad
Kadia, Tapan M.
Konopleva, Marina
Jain, Nitin
Short, Nicholas James
Issa, Ghayas C.
Jeanis, Vicky
Moore, H. Gal
Garris, Rebecca S.
Garcia-Manero, Guillermo
Cortes, Jorge E.
O'Brien, Susan Mary
Jabbour, Elias
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif Irvine, Irvine, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7025
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Outcome with the hyper-CVAD and imatinib mesylate regimen as frontline therapy for adult Philadelphia (Ph) positive acute lymphocytic leukemia (ALL).
    Thomas, Deborah A.
    Kantarjian, Hagop M.
    Cortes, Jorge
    Faderl, Stefan
    Giles, Francis
    Garcia-Manero, Guillermo
    Wierda, William
    Ferrajoli, Alessandra
    Ravandi-Kashani, Farhad
    Verstovsek, Srdan
    Andreeff, Michael
    Letvak, Laurie A.
    Jones, Dan
    Champlin, Richard
    O'Brien, Susan
    BLOOD, 2006, 108 (11) : 87A - 88A
  • [42] Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
    Richard-Carpentier, Guillaume
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    Patel, Keyur P.
    Roberts, Kathryn G.
    Gu, Zhaohui
    Ravandi, Farhad
    Jain, Nitin
    Short, Nicholas J.
    Garcia-Manero, Guillermo
    Schroeder, Heather M.
    Kwari, Monica
    Garris, Rebecca
    Khouri, Rita
    Jones, Mike
    Loiselle, Christopher
    Cortes, Jorge E.
    Sasaki, Koji
    Issa, Ghayas C.
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Verstovsek, Srdan
    Daver, Naval G.
    Mullighan, Charles G.
    O'Brien, Susan M.
    Jabbour, Elias
    BLOOD, 2019, 134
  • [43] The Importance of Ponatinib (Iclusig®) in the Treatment of Philadelphia-Chhromosome-positive acute lymphoblastic Leukemia (Ph plus ALL)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (12)
  • [44] A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
    Nguyen, Daniel
    Jabbour, Elias
    Short, Nicholas
    Issa, Ghayas C.
    Yilmaz, Musa
    Daver, Naval
    Pemmaraju, Naveen
    Chien, Kelly S.
    Masarova, Lucia
    Ravandi, Farhad
    Jain, Nitin
    Deen, Wuliamatu
    Zhao, Min
    Loiselle, Christopher
    Waller, Lourdes
    Banks, Glenda
    Garris, Rebecca
    Kantarjian, Hagop
    BLOOD, 2022, 140 : 6127 - 6129
  • [45] First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).
    Jabbour, Elias
    Kantarjian, Hagop M.
    Aldoss, Ibrahim
    Montesinos, Pau
    Leonard, Jessica Taft
    Gomez-Almaguer, David
    Baer, Maria R.
    Gambacorti-Passerini, Carlo
    McCloskey, James
    Minami, Yosuke
    Papayannidis, Cristina
    Geraldo Rocha, Vanderson
    Rousselot, Philippe
    Vachhani, Pankit
    Wang, Eunice S.
    Wang, Bingxia
    Hennessy, Meliessa
    Vorog, Alexander
    Patel, Niti
    Ribera, Josep-Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36_SUPPL) : 398868 - 398868
  • [46] First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).
    Jabbour, Elias
    Kantarjian, Hagop M.
    Aldoss, Ibrahim
    Montesinos, Pau
    Leonard, Jessica Taft
    Gomez-Almaguer, David
    Baer, Maria R.
    Gambacorti-Passerini, Carlo
    McCloskey, James
    Minami, Yosuke
    Papayannidis, Cristina
    Rocha, Vanderson Geraldo
    Rousselot, Philippe
    Vachhani, Pankit
    Wang, Eunice S.
    Wang, Bingxia
    Hennessy, Meliessa
    Vorog, Alexander
    Patel, Niti
    Ribera, Josep-Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [47] Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib
    Morita, Kiyomi
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Sasaki, Koji
    Jain, Nitin
    Konopleva, Marina
    Short, Nicholas J.
    Takahashi, Koichi
    Khouri, Rita
    Nasnas, Patrice
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    Daver, Naval
    Bravo, Guillermo Montalban
    Issa, Ghayas C.
    Cortes, Jorge E.
    Jabbour, Elias
    BLOOD, 2020, 136
  • [48] Outcome after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen for Adults with De Novo or Minimally Treated Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
    Thomas, Deborah A.
    Kantarjian, Hagop M.
    Cortes, Jorge
    Ravandi, Farhad
    Faderl, Stefan
    Jones, Dan
    Letvak, Laurie A.
    Kebriaei, Partow
    Champlin, Richard E.
    O'Brien, Susan
    BLOOD, 2008, 112 (11) : 1008 - 1008
  • [49] Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis
    Sasaki, Koji
    Kantarjian, Hagop M.
    Short, Nicholas J.
    Ravandi, Farhad
    Khouri, Maria
    Garcia-Manero, Guillermo
    Daver, Naval G.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Jain, Nitin
    Issa, Ghayas C.
    Jacob, Jovitta
    Garris, Rebecca E.
    Yilmaz, Musa
    Thompson, Philip A.
    Nasnas, Patrice
    Pemmaraju, Naveen
    Cortes, Jorge E.
    O'Brien, Susan M.
    Jabbour, Elias J.
    BLOOD, 2018, 132
  • [50] A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+acute lymphoblastic leukemia (ALL): Updated results.
    Bazarbachi, Abdul Hamid
    Yilmaz, Musa
    Ravandi, Farhad
    Thomas, Deborah A.
    Khouri, Maria
    Garcia-Manero, Guillermo
    Garris, Rebecca S.
    Cortes, Jorge E.
    Short, Nicholas James
    Sasaki, Koji
    Issa, Ghayas C.
    Koller, Paul B.
    Kadia, Tapan M.
    Verstovsek, Srdan
    Daver, Naval Guastad
    Jain, Nitin
    Konopleva, Marina
    O'Brien, Susan Mary
    Jabbour, Elias
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345